Details of the Drug Combinations

General Information of This Drug (ID: DMLOQ1V)

Drug Name

Tasimelteon DMLOQ1V

Synonyms

Tasimelteon; 609799-22-6; Hetlioz; VEC-162; BMS-214778; VEC 162; UNII-SHS4PU80D9; BMS 214778; SHS4PU80D9; CHEBI:79042; N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide; Tasimelteon [USAN:INN]; tasimelteonum; N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide; N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide; N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide; Hetlioz (TN); Tasimelteon (USAN/INN); SCHEMBL3505912; GTPL7393

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ethanol + Tasimelteon	DCVJD2N	Ethanol	Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol	[2]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
2	ClinicalTrials.gov (NCT01578057) Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol